2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
Galeterone is an agent in development for this patient population, Taplin explains. It has a unique mechanism of action in that in addition to being an androgen receptor antagonist and a CYP17 lyase inhibitor, it also degrades the androgen receptor.
For this trial, patients will be screened for the presence of a blood-biomarker AR-V7. Patients who are AR-V7—positive and enrolled on the study will be randomized to receive galeterone or enzalutamide (Xtandi), with a primary endpoint of radiographic progression-free survival.